Literature DB >> 14600771

Relapses in Wilms tumour.

Carl-Magnus Kullendorff1.   

Abstract

During an 18-year period, 54 children were treated for Wilms tumour (WT). Thirteen of them, 6 boys and 7 girls, had a relapse. Mean age at diagnosis was 50 months, range 5-233 months. The investigations revealed stage I in 5 cases, stage II in 2, stage III in 3, stage IV in 1 and stage V in 2.The histology was favourable in 6 cases, intermediate in 4 and unfavourable in 3. Clonal chromosome aberrations were detected in 8 cases. The mean time to first relapse was 17 months, range 1-76 months. The location was the local region in 3 cases, other kidney in 3, lungs in 7 and skeletal in 2. A second relapse occurred in 6 patients and a third relapse in 2 patients. Seven patients died after a mean follow-up of 84 months, range 42-180 months, from primary treatment. The 6 surviving children had no evidence of disease after a mean follow-up of 70 months, range 42-120 months, after treatment ended. High stage at diagnosis, unfavourable histologic subtype and occurrence of nephroblastomatosis were found not only in the children with relapse. No significant correlations were found when comparing the karyotypic features with clinical outcome. All 3 tumours with deletions of chromosome arm 16q metastasized.

Entities:  

Mesh:

Year:  2003        PMID: 14600771     DOI: 10.1007/s00383-003-0982-9

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  14 in total

1.  Patterns of abdominal relapse and role of sonography in Wilms tumor.

Authors:  Najat C Daw; William M Kauffman; Sara M Bodner; Charles B Pratt; Fredric A Hoffer
Journal:  Pediatr Hematol Oncol       Date:  2002-03       Impact factor: 1.969

2.  Management of metastatic Wilms tumor: an eleven year experience.

Authors:  D Misra; D K Gupta; D K Mitra; V Bhatnagar; M Bajpai; M Mathur; M Rohatgi
Journal:  Indian J Cancer       Date:  1996-03       Impact factor: 1.224

3.  Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.

Authors:  S Hing; Y J Lu; B Summersgill; L King-Underwood; J Nicholson; P Grundy; R Grundy; M Gessler; J Shipley; K Pritchard-Jones
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.

Authors:  P Grundy; P Telzerow; J Moksness; N E Breslow
Journal:  Med Pediatr Oncol       Date:  1996-11

5.  Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.

Authors:  A M Abu-Ghosh; M D Krailo; S C Goldman; R S Slack; V Davenport; E Morris; J H Laver; G H Reaman; M S Cairo
Journal:  Ann Oncol       Date:  2002-03       Impact factor: 32.976

6.  Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital.

Authors:  Jeffrey S Dome; Tiebin Liu; Matthew Krasin; Lennie Lott; Patricia Shearer; Najat C Daw; Catherine A Billups; Judith A Wilimas
Journal:  J Pediatr Hematol Oncol       Date:  2002 Mar-Apr       Impact factor: 1.289

7.  16q heterozygosity loss in Wilms' tumour in children and its clinical importance.

Authors:  G Skotnicka-Klonowicz; P Rieske; J Bartkowiak; S Szymik-Kantorowicz; P Daszkiewicz; M Debiec-Rychter
Journal:  Eur J Surg Oncol       Date:  2000-02       Impact factor: 4.424

8.  Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4.

Authors:  R C Shamberger; K A Guthrie; M L Ritchey; G M Haase; J Takashima; J B Beckwith; G J D'Angio; D M Green; N E Breslow
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

Review 9.  The management of relapsed Wilms tumor.

Authors:  J S Miser; M F Tournade
Journal:  Hematol Oncol Clin North Am       Date:  1995-12       Impact factor: 3.722

10.  Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour.

Authors:  R G Grundy; J Pritchard; P Scambler; J K Cowell
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.